Format

Send to

Choose Destination
Dermatol Online J. 2017 Jan 15;23(1). pii: 13030/qt206538zm.

Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab.

Author information

1
Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid. aromerom@salud.madrid.org.

Abstract

We report a 52-year old woman with a 28-year historyof disfiguring facial discoid lupus erythematosus(DLE), persistent despite both classical therapiesand rituximab. Ustekinumab 45 mg was started incombination with methotrexate and intralesionalcorticosteroids. Methotrexate and intralesionalcorticosteroids were withdrawn 30 months later andustekinumab maintained as monotherapy. Fortyeight months later stable improvement was achievedwithout side effects. Only nine patients with cutaneouslupus erythematosus (CLE) treated with ustekinumabhave been reported to date. Ustekinumab could be apromising alternative in severe and recalcitrant casesof CLE. Possibly, the Th17-inflammation pathway isplaying a role in these patients.

PMID:
28329473
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center